US equities |
SPCX $167.13 ▲+5.14% NVDA $236.33 ▲+1.02% MU $1,064.78 ▼-0.94% TSLA $378.54 ▲+2.14% MSFT $525.08 ▲+1.46% SNDK $1,709.36 ▼-0.62% INTC $117.36 ▼-1.66% META $744.61 ▲+2.27%
FinancialContent

Fractyl Health, Inc. - Common Stock (NQ:GUTS)

4.455 +4.045 (+986.59%)
Delayed Quote Updated: 12:25 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fractyl Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Faruqi & Faruqi, LLP Urges Fractyl Health, Inc. (NASDAQ: GUTS) Investors to Seek Counsel Before the October 20, 2026 Lead Plaintiff Deadline in the Securities Class Action
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Fractyl Health, Inc. (GUTS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
Fractyl Health Inc (NASDAQ:GUTS) Q1 Earnings: Net Income Swing Masks Core Operating Burn as Key Revita Data Readout Looms ↗
Via Chartmill
Fractyl Health (NASDAQ:GUTS) Posts Narrower-Than-Expected Loss Ahead of Pivotal Trial Readout ↗
Via Chartmill
News headline image
Stockholder Alert: Robbins LLP Informs Investors of the Fractyl Health, Inc. Class Action
From Robbins LLP
Via Business Wire
News headline image
Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Eyes Q4 Revita Data, Launches Rejuva Gene Therapy Trial ↗
Fractyl Health (NASDAQ:GUTS) is advancing two one-time treatment approaches intended to provide durable benefits for obesity, type 2 diabetes and related metabolic diseases, Chief Executive Officer... 
Via MarketBeat
News headline image
Fractyl Health Q2 Earnings Call Highlights ↗
Fractyl Health (NASDAQ:GUTS) said its Revita endoscopic procedure showed durable weight-maintenance results one year after patients discontinued GLP-1 therapy, while the company reaffirmed plans to... 
Via MarketBeat
Topics Earnings
News headline image
Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Participate in Upcoming Investor Events
From Fractyl Health, Inc.
Via GlobeNewswire
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Fractyl Health Says Revita Helped Patients Keep Weight Off After Stopping GLP-1s ↗
Fractyl Health (NASDAQ:GUTS) reported one-year data from the randomized midpoint cohort of its REMAIN-1 study, saying its Revita procedure helped patients maintain a larger share of GLP-1-induced... 
Via MarketBeat
News headline image
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy
Experienced market access leader joins to build reimbursement and health economic infrastructure for Revita® ahead of anticipated REMAIN-1 Pivotal Cohort topline data in early Q4 2026 
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Q1 Earnings Call Highlights ↗
Fractyl Health (NASDAQ:GUTS) said it remains on track to report pivotal data for its Revita therapy in early fourth quarter 2026, as management highlighted clinical, regulatory and reimbursement... 
Via MarketBeat
Topics Earnings
News headline image
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference
From Fractyl Health, Inc.
Via GlobeNewswire
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
From DJS Law Group
Via Business Wire
News headline image
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
From The DJS Law Group
Via Business Wire
Top movers in Thursday's session ↗
Via Chartmill
Curious about the most active stocks on Thursday? ↗
Via Chartmill
Keep an eye on the top gainers and losers in Thursday's session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 Next >